Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 589 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05717738Recruiting
Immunotherapy plus targeted drugs after TACE for liver cancer
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
Quanzhou, FujianAges 18 years+ - NCT05809869RecruitingPhase 2
Immunotherapy plus liver radiation for metastatic liver cancer
This trial tests whether combining an immunotherapy drug with a special type of liver radiation (yttrium-90) can control metastatic hepatocellular carcinoma (liver cancer that has spread). It may help by boosting your immune system and shrinking liver tumors at the same time.
Hong KongAges 18 years+ - NCT05810402Recruiting
Testing immunotherapy for advanced liver cancer using blood tests
This study looks at how well immune-checkpoint therapy (a PD-1 or PD-L1 immunotherapy) works for advanced liver cancer, using “liquid biopsy” blood testing to guide or monitor care. It may help your team better track your cancer and response without needing repeated tissue biopsies.
MontpellierAges 18 years+ - NCT05842174RecruitingPhase 1/Phase 2
Checking a new treatment approach for liver cancer needing TACE
This early-stage trial studies a new strategy for hepatocellular carcinoma (a type of liver cancer) in people who are planned to receive TACE, a procedure that delivers treatment through the liver’s blood supply. It aims to test whether targeting a specific cell survival process can improve how well the treatment works and is tolerated.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05871892Recruiting
PET/CT or PET/MRI scans for suspected or diagnosed liver cancer
This study looks at how well special imaging scans (PET/CT or PET/MRI) work in adults with suspected or diagnosed liver cancer. It may help doctors better see the cancer and plan next steps.
AarhusAges 18–100 - NCT05901519RecruitingPhase 2
Prednisone to protect the liver during focused radiation for liver cancer
This trial tests whether prednisone (an anti-inflammatory steroid) can help protect the liver in people with hepatocellular carcinoma who are getting stereotactic body radiation therapy. It may reduce liver stress from radiation and help you tolerate treatment safely.
Ann Arbor, MichiganAges 18 years+ - NCT05926726Recruiting
GPC3-targeted CAR-T for advanced liver cancer
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
ShanghaiAges 18–75 - NCT05954897RecruitingPhase 2
Lenvatinib plus tislelizumab with HAIC for advanced liver cancer
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
Guangzhou, GuangdongAges 18 years+ - NCT05992220RecruitingPhase 2
Immunotherapy with or without radiation for liver cancer
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
SeoulAges 20–79 - NCT06034977RecruitingPhase 2
ADI-PEG 20 and Lenvatinib for liver cancer
This trial tests a combination of two drugs, ADI-PEG 20 and Lenvatinib, for people with advanced liver cancer that cannot be removed by surgery. It aims to see if this combination can help shrink or control the cancer.
TaoyuanAges 18 years+ - NCT06044506RecruitingPhase 1
Natural killer cell therapy for liver cancer
This study tests an experimental therapy using your own natural killer cells to fight liver cancer. It may be an option if you have a specific stage of liver cancer and are generally in good health.
Jakarta Pusat, Jakarta Special Capital RegionAges 20–60 - NCT06178198RecruitingPhase 2
Radiation and liver surgery for large liver tumors
This trial tests combining radiation therapy (radioembolization) with surgery to remove part of the liver for people with a single large liver tumor (over 8 cm) that hasn't spread. The goal is to see if this approach can treat the tumor effectively.
Seoul, SeoulAges 18 years+ - NCT06241326Recruiting
Immunotherapy for liver cancer study
This trial tests immunotherapy-based combinations for liver cancer. It may help if your doctor thinks this treatment could benefit you.
Nanjing, JiangsuAges 18 years+ - NCT06244225RecruitingPhase 2
Triple therapy for advanced liver cancer (HAIC + sintilimab + donafenib)
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
Wuhan, HubeiAges 18 years+ - NCT06326502RecruitingPhase 1
A study of ETN101 for advanced liver cancer
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
SeoulAges 19–65 - NCT06333561Recruiting
Combination therapy for infiltrative liver cancer
This trial tests a three-drug combination for a specific type of liver cancer called infiltrative hepatocellular carcinoma. It combines a liver-directed chemotherapy infusion (HAIC) with two oral and intravenous drugs (lenvatinib and a PD-1 inhibitor) to see if it works better than lenvatinib alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06339424RecruitingPhase 2
Atezolizumab and Bevacizumab with radiation for liver cancer that can't be removed
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
Taoyuan City, TaiwanAges 18 years+ - NCT06371157RecruitingPhase 3
Testing AK104 and Lenvatinib with TACE for liver cancer
This trial tests if adding a new combination of drugs (AK104 and lenvatinib) to a standard liver cancer procedure called TACE is more effective than TACE alone. It is for people whose liver cancer has not spread and cannot be removed by surgery, but who are well enough to receive these treatments.
Zhengzhou, HenanAges 18–75 - NCT06375486RecruitingPhase 2
Ivonescimab and HAIC for Unresectable Liver Cancer
This trial tests a combination of a targeted immunotherapy drug (ivonescimab) and a liver-directed chemotherapy infusion (HAIC) for people with liver cancer that cannot be removed by surgery. It may be an option if you have not had prior systemic treatment for your liver cancer.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06405321Recruiting
Initial therapy before surgery for liver cancer
This trial looks at how well certain initial treatments (like targeted therapy, immunotherapy, or liver-directed procedures) work in people with liver cancer who have not had surgery yet. It aims to see if these treatments can shrink the tumor enough to allow removal later.
Nanning, ChinaAges 18–75 - NCT06406634RecruitingPhase 2
Cadonilimab, Lenvatinib, and HAIC for Unresectable Liver Cancer
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Changsha, HunanAges 18–75 - NCT06446154RecruitingPhase 2
Fruquintinib after immunotherapy for advanced liver cancer
This trial tests a new drug called fruquintinib for people with advanced liver cancer who have already tried immunotherapy. It may help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT06463522RecruitingPhase 1/Phase 2
Immune cell therapy for liver cancer
This trial tests using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It may help if you have Barcelona Clinic Liver Cancer (BCLC) stage B or C and your liver function is still fairly good.
BeijingAges 18–70 - NCT06519578Recruiting
Liver Cancer Study: Comparing Two Chemotherapy Drugs via Artery Infusion
This study compares two chemotherapy drugs (raltitrexed and 5-fluorouracil) given directly into the liver's main artery to treat liver cancer. It aims to see which drug works better and is safer for people with hepatocellular carcinoma.
ShanghaiAges 18–75
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 589 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.